Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

Table 4 Changes of TE scores (kPa) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated

	Crude model		Adjusted for baseline age, gender, ethnicity
	Coefficient β (95% CI)	p-value	Coefficient β (95% CI)	p-value
(Intercept)	5.088 (4.693, 5.483)	< 0.001	4.586 (3.385, 5.787)	< 0.001
Group	1.758 (0.977, 2.540)	< 0.001	1.729 (0.926, 2.533)	< 0.001
Time	0.006 (− 0.008, 0.020)	0.416	0.006 (− 0.008, 0.020)	0.421
Group x Time ^a	−0.038 (− 0.065, − 0.011)	0.006	−0.040 (− 0.067, − 0.013)	0.004

^a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. CI confidence interval; TDF Tenofovir disoproxil fumarate

ISSN: 1471-2334